Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AbbVie is conducting a clinical study titled ‘A First In Human Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-319 in B-cell Malignancies’. The study aims to assess the safety and efficacy of ABBV-319 in treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and chronic lymphocytic leukemia (CLL), which are aggressive forms of cancer affecting the immune system.
The intervention being tested is ABBV-319, an investigational drug administered intravenously. It is designed to treat patients with relapsed or refractory B-cell lymphomas, including DLBCL, FL, and CLL, by determining effective dosage levels and observing changes in disease activity.
The study follows a non-randomized, sequential intervention model with no masking, focusing on treatment. It includes a dose escalation phase to establish optimal dosing, followed by a dose expansion phase to evaluate disease activity changes.
The study began on April 26, 2023, with an estimated completion date in August 2025. The latest update was submitted on August 12, 2025. These dates are crucial for tracking the study’s progress and potential market impact.
This study could significantly influence AbbVie’s stock performance, as successful results may enhance the company’s position in the oncology market. Investors should monitor this study’s progress, especially considering the competitive landscape in cancer treatment.
The study is currently recruiting, with further details available on the ClinicalTrials portal.